stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Revenue growth
Fortrea Holdings Inc.'s revenue growth over the twelve months to 30 September 2026 was −3.38%, down 4.4 percentage points from fiscal 2025 (1.00%). Over the past ten years it has ranged from −7.21% (fiscal 2022) to 18.5% (fiscal 2021); the current reading is higher than 80% of that period. That is below the Biotechnology industry median of 6.76% and below the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 1.00% | 6.14 |
| FY2024 | −5.14% | (5.33) |
| FY2023 | 0.19% | 7.40 |
| FY2022 | −7.21% | (25.72) |
| FY2021 | 18.5% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −1.40% | 3.12 |
| Jun 2026 | −4.52% | (2.25) |
| Mar 2026 | −2.27% | 2.97 |
| Dec 2025 | −5.24% | (9.15) |
| 9 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| VIR Vir Biotechnology, Inc. compare | 1,696.0% |
| BHVN Biohaven Ltd. compare | 425.2% |
| HRMY Harmony Biosciences Holdings, Inc. compare | 19.8% |
| IMNM Immunome, Inc. compare | 16.7% |
| FTRE Fortrea Holdings Inc. | −3.38% |
| SRPT Sarepta Therapeutics, Inc. compare | −19.0% |
| ZYME Zymeworks Inc. compare | −69.8% |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
| Biotechnology industry median | 6.76% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|